Sanofi (NASDAQ:SNY) Downgraded by StockNews.com

by · The Cerbat Gem

StockNews.com downgraded shares of Sanofi (NASDAQ:SNY – Free Report) from a strong-buy rating to a buy rating in a report released on Monday.

SNY has been the topic of a number of other reports. Argus lifted their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Get Our Latest Analysis on SNY

Sanofi Stock Up 0.8 %

Shares of Sanofi stock opened at $54.86 on Monday. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The stock has a 50 day moving average price of $56.05 and a two-hundred day moving average price of $51.48. The stock has a market capitalization of $139.21 billion, a P/E ratio of 29.82, a PEG ratio of 1.57 and a beta of 0.60.

Sanofi (NASDAQ:SNY – Get Free Report) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. Sanofi’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.95 EPS. Equities analysts expect that Sanofi will post 4.26 earnings per share for the current year.

Hedge Funds Weigh In On Sanofi

Several large investors have recently added to or reduced their stakes in the company. POM Investment Strategies LLC acquired a new position in shares of Sanofi in the 2nd quarter valued at $25,000. Register Financial Advisors LLC bought a new position in Sanofi during the first quarter worth about $29,000. Larson Financial Group LLC boosted its holdings in Sanofi by 480.8% during the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after purchasing an additional 500 shares in the last quarter. Palisade Asset Management LLC bought a new stake in shares of Sanofi in the 1st quarter valued at approximately $31,000. Finally, Arrow Financial Corp acquired a new position in shares of Sanofi in the 2nd quarter worth approximately $35,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Company Profile

(Get Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Featured Stories